Page 15 - 《中国药房》2025年3期

参考文献 KEYNOTE-585：phase Ⅲ study of perioperative chemo‐
[ 1 ] THRIFT A P，EL-SERAG H B. Burden of gastric cancer therapy with or without pembrolizumab for gastric cancer
[J]. Clin Gastroenterol Hepatol，2020，18（3）：534-542. [J]. Future Oncol，2019，15（9）：943-952.
[ 2 ] 李益潮，魏芯芯，周凤军，等. 胃癌发病相关影响因素研 [11] JANJIGIAN Y Y，AL-BATRAN S E，WAINBERG Z A，
究进展[J]. 肿瘤代谢与营养电子杂志，2023，10（4）： et al. LBA73 pathological complete response （pCR） to
562-566. durvalumab plus 5-fluorouracil，leucovorin，oxaliplatin
LI Y C，WEI X X，ZHOU F J，et al. Research progress on and docetaxel （FLOT） in resectable gastric and gastro‐
related factors of gastric cancer morbidity[J]. Electron J esophageal junction cancer （GC/GEJC）：interim results of
Metab Nutr Cancer，2023，10（4）：562-566. the global，phase Ⅲ MATTERHORN study[J]. Ann On‐
[ 3 ] ZENG H M，ZHENG R S，SUN K X，et al. Cancer sur‐ col，2023，34：S1315-S1316.
vival statistics in China 2019-2021：a multicenter， [12] LI C，ZHENG Y，SHI Z，et al. 1512MO perioperative
population-based study[J]. J Natl Cancer Cent，2024，4 camrelizumab （C） combined with rivoceranib （R） and
（3）：203-213. chemotherapy （chemo） versus chemo for locally ad‐
[ 4 ] KANG Y K，YOOK J H，PARK Y K，et al. PRODIGY：a vanced resectable gastric or gastroesophageal junction （G/
phase Ⅲ study of neoadjuvant docetaxel，oxaliplatin，and GEJ） adenocarcinoma：the first interim analysis of a ran‐
S-1 plus surgery and adjuvant S-1 versus surgery and adju‐ domized，phase Ⅲ trial （DRAGON IV）[J]. Ann Oncol，
vant S-1 for resectable advanced gastric cancer[J]. J Clin 2023，34：S852.
Oncol，2021，39（26）：2903-2913. [13] ANDRÉ T，TOUGERON D，PIESSEN G，et al. Neoadju‐
[ 5 ] ZHANG X T，LIANG H，LI Z Y，et al. Perioperative or vant nivolumab plus ipilimumab and adjuvant nivolumab
postoperative adjuvant oxaliplatin with S-1 versus adju‐ in localized deficient mismatch repair/microsatellite
vant oxaliplatin with capecitabine in patients with locally instability-high gastric or esophagogastric junction adeno‐
advanced gastric or gastro-oesophageal junction adenocar‐ carcinoma：the GERCOR NEONIPIGA phase Ⅱ study[J].
cinoma undergoing D2 gastrectomy （RESOLVE）：an J Clin Oncol，2023，41（2）：255-265.
open-label，superiority and non-inferiority，phase 3 ran‐ [14] PIETRANTONIO F，RAIMONDI A，LONARDI S，et al.
domised controlled trial[J]. Lancet Oncol，2021，22（8）： INFINITY：a multicentre，single-arm，multi-cohort，phase
1081-1092. Ⅱ trial of tremelimumab and durvalumab as neoadjuvant
[ 6 ] JIANG Z C，XIE Y B，ZHANG W，et al. Perioperative treatment of patients with microsatellite instability-high
chemotherapy with docetaxel plus oxaliplatin and S-1 （MSI） resectable gastric or gastroesophageal junction ad‐
（DOS） versus oxaliplatin plus S-1 （SOX） for the treat‐ enocarcinoma （GAC/GEJAC）[J]. J Clin Oncol，2023，41
ment of locally advanced gastric or gastro-esophageal （Suppl. 4）：358.
junction adenocarcinoma （MATCH）：an open-label，ran‐ [15] AL-BATRAN S E，LORENZEN S，THUSS-PATIENCE P
domized，phase 2 clinical trial[J]. Gastric Cancer，2024，27 C，et al. Surgical and pathological outcome，and pathologi‐
（3）：571-579. cal regression，in patients receiving perioperative atezoli‐
[ 7 ] AL-BATRAN S E，HOMANN N，PAULIGK C，et al. Peri‐ zumab in combination with FLOT chemotherapy versus
operative chemotherapy with fluorouracil plus leucovorin， FLOT alone for resectable esophagogastric adenocarci‐
oxaliplatin， and docetaxel versus fluorouracil or noma：interim results from DANTE，a randomized，multi‐
capecitabine plus cisplatin and epirubicin for locally ad‐ center，phase Ⅱb trial of the FLOT-AIO German gastric
vanced，resectable gastric or gastro-oesophageal junction cancer group and Swiss SAKK[J]. J Clin Oncol，2022，40
adenocarcinoma （FLOT4）：a randomised，phase 2/3 trial （Suppl. 16）：4003.
[J]. Lancet，2019，393（10184）：1948-1957. [16] SAKURAMOTO S，SASAKO M，YAMAGUCHI T，et al.
[ 8 ] JAMEL S，MARKAR S R，MALIETZIS G，et al. Progno- Adjuvant chemotherapy for gastric cancer with S-1，an
stic significance of peritoneal lavage cytology in staging oral fluoropyrimidine[J]. N Engl J Med，2007，357（18）：
gastric cancer：systematic review and meta-analysis[J]. 1810-1820.
Gastric Cancer，2018，21（1）：10-18. [17] BANG Y J，KIM Y W，YANG H K，et al. Adjuvant
[ 9 ] COCCOLINI F，COTTE E，GLEHEN O，et al. Intraperito‐ capecitabine and oxaliplatin for gastric cancer after D2
neal chemotherapy in advanced gastric cancer：meta- gastrectomy （CLASSIC）：a phase 3 open-label，randomised
analysis of randomized trials[J]. Eur J Surg Oncol，2014， controlled trial[J]. Lancet，2012，379（9813）：315-321.
40（1）：12-26. [18] YOSHIDA K，KODERA Y，KOCHI M，et al. Addition of
[10] BANG Y J，VAN CUTSEM E，FUCHS C S，et al. docetaxel to oral fluoropyrimidine improves efficacy in

中国药房 2025年第36卷第3期 China Pharmacy 2025 Vol. 36 No. 3 · 265 ·